Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad268 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Atsuyuki Igarashi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Maruho Co. Ltd, Chugai Pharmaceutical Co. Ltd.
Abstract (Originalsprache)
Background
Atopic dermatitis (AD) is a chronic, inflammatory skin condition affecting up to one-quarter of children. Uncontrolled pruritus associated with childhood AD, and the accompanying scratching, negatively impacts quality of life (QoL), sleep and development. The humanized monoclonal antibody nemolizumab, used concomitantly with topical agents, was shown to reduce pruritus and improve QoL in patients with AD aged ≥ 13 years. However, data relating to its efficacy and safety in younger children (aged < 13 years) have been lacking.
Objectives
To evaluate the efficacy and safety of nemolizumab, administered concomitantly with topical agents, in Japanese paediatric patients (aged 6–12 years) with AD and inadequately controlled moderate-to-severe pruritus.
Methods
This was a randomized, placebo-controlled, double-blind, parallel-group, multicentre, 16-week, phase III study. Patients aged ≥ 6 and < 13 years, with confirmed AD, and an inadequate pruritic response despite treatment with topical agents and oral antihistamines were randomly assigned (1 : 1) to receive nemolizumab 30 mg or placebo every 4 weeks (Q4W). The primary efficacy endpoint was the change in the weekly mean 5-level itch score from baseline to week 16; secondary efficacy endpoints were related to pruritus, indicators for AD and QoL. Safety was assessed via adverse events (AEs) and laboratory test results.
Results
In total, 89 patients were enrolled, received either nemolizumab 30 mg (n = 45) or placebo (n = 44) Q4W, and completed the study. The mean patient age was 9.1 (SD 1.9) years, and mean duration of AD was 8.5 (2.7) years. The change in 5-level itch score from baseline to week 16 showed a statistically significant difference in the nemolizumab treatment group (−1.3) compared with placebo (−0.5; least-squares mean difference −0.8, 95% confidence interval −1.1 to −0.5; P < 0.0001). Improvements with nemolizumab were observed from the second day of administration. Secondary endpoints were in favour of nemolizumab. No AEs resulted in discontinuation, and the overall safety profile in patients aged 6–12 years was comparable with that in older patients (aged ≥ 13 years) with AD.
Conclusions
Nemolizumab is a potential new treatment option for paediatric patients with AD whose pruritus has not been sufficiently improved with topical treatments and antihistamines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, NTT Medical Center Tokyo, Tokyo, Japan.
- Department of Pediatrics, Daisan Hospital, The Jikei University School of Medicine, Tokyo, Japan.
- Clinical Development Department, Maruho Co. Ltd, Kyoto, Japan.
ORCID-Profile: Atsuyuki Igarashi, Toshio Katsunuma, Takayo Matsumura, Hiroshi Komazaki
Förderung
- Maruho Co. Ltd
- Chugai Pharmaceutical Co. Ltd
Zitieren
APA
Igarashi, A., Katsunuma, T., Matsumura, T., Komazaki, H., & Nemolizumab-JP04 Study Group (2023). Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad268
Vancouver
Igarashi A, Katsunuma T, Matsumura T, Komazaki H, Nemolizumab-JP04 Study Group. Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad268
BibTeX
@article{Igarashi2023,
author = {Igarashi, Atsuyuki and Katsunuma, Toshio and Matsumura, Takayo and Komazaki, Hiroshi and Nemolizumab-JP04 Study Group, Nemolizumab-JP04 Study Group},
title = {Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad268}
}
EUVIMED